TECHNOLOGY

Do you rely on plasmid DNA for the production of vaccines and therapeutics? There is a way to avoid bottlenecks and expedite your development pipeline, by utilizing synthetic DNA, with a fully enzymatic manufacturing process it comes with a host of benefits that make it well worth the switch

The future is synthetic

Enzymatic manufacturing process

4basebio’s synthetic DNA is produced via an enzymatic, cell-free manufacturing process. It overcomes the significant manufacturing challenges experienced with plasmid DNA. By eliminating the need for bacterial fermentation, synthetic DNA offers enhanced safety, speed and scalability.

Enzymatic manufacturing process

4basebio’s synthetic DNA is produced via an enzymatic, cell-free manufacturing process. It overcomes the significant manufacturing challenges experienced with plasmid DNA. By eliminating the need for bacterial fermentation, synthetic DNA offers enhanced safety, speed and scalability.

Synthetic DNA: Faster, cleaner, safer alternative

No bacterial sequences present in the final DNA product.

Enhanced safety

Move from sequence to GMP production in as little as 8 weeks.

Accelerated timelines

Reduced DNA requirements in end applications

Increased efficiency

Complex sequences ranging from 140 bp to 20 kb.

Unmatched flexibility

Added benefits of synthetic DNA for mRNA manufacturing

Synthetic DNA has further benefits for mRNA manufacturing, due to its linear open format, it doesn’t require enzymatic linearisation before feeding into IVT reactions. Longer polyA tails can be efficiently and reliably included directly in the DNA template, to enhance the stability and translational capacity of the mRNA.


TruePrime® technology for synthetic DNA production

4basebio utilises a proprietary technology for primer-free DNA amplification called TruePrime®, which enables high-yields and high-quality DNA production. By combining two unique enzymes, TruePrime® technology achieves continuous enzymatic priming with faithful and processive strand-displacement elongation for efficient isothermal DNA amplification. This innovative method supports DNA constructs from 140 bp to 20 kb without sequence bias or primer-related artifacts, making it suitable for any DNA starting material.

Applications

See how synthetic DNA is driving innovation in mRNA vaccines & therapeutics, gene editing, cell and gene therapies and DNA vaccines


Manufacturing

Discover our RUO, HQ, and GMP-grade synthetic DNA, designed for every stage from discovery to commercial production